Corvus Pharmaceuticals, Inc.
CRVS · Nasdaq · USD · Market cap $888M · 37 employees
Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, engages in the development of product candidates that precisely target proteins that are critical to immune cell maturation and function in the Un…
FAIL · Does not pass the screenPrice as of 20 Nov 2026Daily close, not a live quote
Screened 2026-11-20 · the tape above runs as of 14:15 UTC · two dates, stated on purpose · verdict and workings shown in full · never trimmed
Key facts today
- Price9.67 USD at the 20 Nov 2026 close
- Fair valueUnder review: our model's value is 2.81x the price, above our 2.00x limit.
- Our regime readMarkup, as of 15 Nov 2026
- Ethical screenDoes not pass
- OptionsOpen interest leans heavily to calls (put/call 0.07)
- Last reviewed20 Nov 2026 (1 day ago)
- Release timesRelease and earnings times on your chart: Event Guard Mentor
A summary of the dated readings below, not a live quote and not advice.
Our fair-value range: range not available (screen dated 2026-11-20).
- Trend Markup
- Insiders insiders bought, latest filing 2026-11-11
- Positioning no disclosures inside 60 days, left as found
- Options put/call open interest 0.07, read 2026-11-20
- Ethical does not pass the values gate
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
This name holds its markup label.
Corvus Pharmaceuticals, Inc. holds its Markup at $9.67. The statistical read favours the sellers, held for 71 days.
| Phase | Markup |
| Quantitative state | The statistical read favours the sellers, held for 71 days |
| Price at the screen | $9.67 |
| Valuation | N/A trailing · -9.89 forward price to earnings |
| Values screen | FAIL · score 70.0 |
| Beta | 1.43 |
Five Screens: CRVS's Results
FAIL. Interest-bearing securities
| Test | Figure | Limit | Status |
|---|---|---|---|
| Business activity | Permissible | Permissible core business | Pass |
| Debt load | 1.32% | Below 33% | Pass |
| Interest-bearing cash | 73.36% | Below 33% | Fail |
| Receivables | 6.49% | Below 49% | Pass |
Definitions, sources and threshold rules: ticker values-screen methodology.
The Ethical ReadWhy It Falls Short, in Plain English
Corvus Pharmaceuticals,'s business is fine, but its cash and interest-bearing securities are about 73% of its assets, well over the ~33% line, so it does not pass on the financial screens.
Read as at 20 Nov 2026. It updates when the underlying figures move, and past reads are kept below. How we screen.
Follow this verdict
Get an email when CRVS's ethical verdict changes
Today CRVS does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
The Fair Value Range
Fair value under review. Our model's value is 2.81x the price, above our 2.00x limit. We show no fair value, margin of safety or value read built on it until the review clears.
The Street's RangeStreet: 7 covering, consensus Strong Buy. Average target +231%.
Clinical Biotech Hits Wall on Missing Data
Picture a lab racing to fine tune immune cells while the cash meter ticks down. Corvus is exactly that, a clinical stage group whose lead candidate targets proteins tied to immune function, yet it posts zero profit margins and a minus thirty per cent return on equity.
The numbers flag a double gap. Fair value sits at twice the current price and analysts eye thirty two dollars, yet the opportunity rating is none because the ethical screen returns insufficient data on basic ratios. Negative forward earnings and an unknown moat simply compound the absence of usable information.
Risk sits in the usual biotech traps of trial failure and dilution, made worse by the lack of any ethical baseline to judge governance or long term viability. Analysis, not advice.
| Forward P/E | -9.9x |
| EPS, trailing | -0.62 |
| EPS, forward | -1.07 |
| Profit margin | 0.0%currently unprofitable |
| Return on equity | -35.4%not currently earning a positive return on equity |
| FCF yield | -3.08% |
| Debt to equity | 0.32minimal debt: a conservative balance sheet |
| Current ratio | 16.16comfortably covers its short-term bills |
| Beta | 1.43moves a little more than the market |
| Short interest, float | 0.23% |
| 52-week range | 6.39 - 26.95 |
| Market cap | $888M |
| Employees | 37 |
CRVS-specific watchpoints · The things to watch: it's a small-cap, so the share price can swing harder than the market; it already moves more than the market on an average day; as a biotechnology name, trial and regulatory outcomes can move it sharply either way.
Metric definitions and interpretation rules: ticker-page methodology.
Every Entry, As Written
The framework has shifted from markdown to markup since the last review.
Earnings landed in this window. Ethical screening: FAIL.
Written on its date, before the outcome; never pruned.
- Corvus Pharmaceuticals (CRVS): This Clinical-Stage Drugmaker Just Got A Lot More Interesting Insider Monkey · 17 Aug 2026
- Corvus Pharmaceuticals (CRVS) Q2 2026 Earnings Call Transcript Motley Fool · 14 Aug 2026
- Corvus Pharmaceuticals Inc (CRVS) (Q2 2026) Earnings Call Highlights: Advancing Soquelitinib ... GuruFocus.com · 7 Aug 2026
- Corvus Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary Moby · 7 Aug 2026
- Corvus Pharmaceuticals Q2 Earnings Call Highlights MarketBeat · 7 Aug 2026
Headlines from third-party outlets, linked for reference: not our reporting, not advice.
Screened names in the same industry · explore each on its own page.
| Date | Insider | Title | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-11 | Arcara Jeffrey | Chief Business Officer | P - Purchase | 4,500 | $50,475 |
Public filings, recorded as found. The full tape lives at Insider Intelligence.
| Period | Price then | Price return | Divs per share | $1,000 became | Total return |
|---|---|---|---|---|---|
| 1 month | $15.81 | -29.0% | · | $710 | -29.0% |
| 2 months | $15.10 | -25.6% | · | $744 | -25.6% |
| 3 months | $16.01 | -29.9% | · | $701 | -29.9% |
| 6 months | $8.40 | +33.7% | · | $1,337 | +33.7% |
| 1 year | $4.25 | +164.2% | · | $2,642 | +164.2% |
| 2 years | $2.10 | +434.8% | · | $5,348 | +434.8% |
| 3 years | $3.58 | +213.7% | · | $3,137 | +213.7% |
| 5 years | $2.80 | +301.1% | · | $4,011 | +301.1% |
Historical returns from market close data. Past performance does not guarantee future results.
This entry now belongs to the ledger. Whatever CRVS does next, these words stay.
Thirteen thousand names carry this page. One desk keeps them honest.
Membership opens the full screen archive, the composites built from it, and the daily coverage that prices what the screen approves.
Join the deskScreening is research, not a fatwa and not financial advice. Figures are drawn from public accounts at the screen date shown. Always manage your risk.